Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;42(12):1407-1433.
doi: 10.1007/s40618-019-01079-6. Epub 2019 Jul 18.

Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults

Affiliations
Review

Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults

C Betterle et al. J Endocrinol Invest. 2019 Dec.

Abstract

Background: Addison's disease (AD) is a rare disorder and among adult population in developed countries is most commonly caused by autoimmunity. In contrast, in children genetic causes are responsible for AD in the majority of patients.

Purpose: This review describes epidemiology, pathogenesis, genetics, natural history, clinical manifestations, immunological markers and diagnostic strategies in patients with AD. Standard care treatments including the management of patients during pregnancy and adrenal crises consistent with the recent consensus statement of the European Consortium and the Endocrine Society Clinical Practice Guideline are described. In addition, emerging therapies designed to improve the quality of life and new strategies to modify the natural history of autoimmune AD are discussed.

Conclusions: Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD.

Keywords: Addison’s disease; Autoimmune polyendocrine syndromes; Natural history of Addison’s disease; Primary adrenal insufficiency; Therapy of Addison’s disease.

PubMed Disclaimer

References

    1. Eur J Cancer. 2018 Jul;97:57-58 - PubMed
    1. J Clin Endocrinol Metab. 2015 Jun;100(6):2171-80 - PubMed
    1. Eur J Endocrinol. 2016 Jan;174(1):97-105 - PubMed
    1. Clin Immunol. 2011 Sep;140(3):291-9 - PubMed
    1. Clin Endocrinol (Oxf). 2001 May;54(5):633-9 - PubMed

Substances

LinkOut - more resources